Drug intelligence / Profile preview

diazepam nasal spray

Development stage: Approved
Lead developer: Neurelis
Modality: Small Molecules
Administration: Intranasal

Overview

Diazepam nasal spray is a benzodiazepine anticonvulsant formulated for intranasal administration. It is used as a short-term treatment for seizure clusters (also known as acute repetitive seizures) that are different from a person's normal seizure pattern. The exact mechanism of action is not fully understood, but it is thought to involve potentiation of GABAergic neurotransmission resulting from binding at the benzodiazepine site of the GABAA receptor. VALTOCO utilizes an absorption enhancement technology called INTRAVAIL to enable noninvasive, enhanced intranasal delivery of diazepam.

Brand names: VALTOCO
Other names: diazepam nasal spray

Targets

GABRR (GABA-A receptor subunit rho)

Beyond the preview

Go deeper on diazepam nasal spray.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on diazepam nasal spray.

Explore the full profile